Irbesartan HCl | CAS#329055-23-4 | angiotensin receptor blocker

MedKoo Cat#: 558125 | Name: Irbesartan HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Irbesartan, also known as BMS-186295, is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. It selectively and competitively blocks the binding of angiotensin II to the angiotensin I receptor. Angiotensin II stimulates aldosterone synthesis and secretion by adrenal cortex, which decreases the excretion of sodium and increases the excretion of potassium. Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle.

Chemical Structure

Irbesartan HCl

CAS#329055-23-4 (HCl)

Theoretical Analysis

MedKoo Cat#: 558125

Name: Irbesartan HCl

CAS#: 329055-23-4 (HCl)

Chemical Formula: C25H29ClN6O

Exact Mass: 428.2300

Molecular Weight: 465.00

Elemental Analysis: C, 64.58; H, 6.29; Cl, 7.62; N, 18.07; O, 3.44

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

329055-23-4 (HCl) 138402-11-6 (free base)

Synonym

Irbesartan HCl; Irbesartan hydrochloride; Irbesartan, Avapro, Aprovel, Karvea, BMS-186295; BMS 186295; BMS186295;

IUPAC/Chemical Name

1,3-Diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)- hydrochloride

InChi Key

ZUYFSRQJPNUOQU-UHFFFAOYSA-N

InChi Code

InChI=1S/C25H28N6O.ClH/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23;/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30);1H

SMILES Code

O=C1N(CC2=CC=C(C3=CC=CC=C3C4=NN=NN4)C=C2)C(CCCC)=NC15CCCC5.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 465.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Zhang F, Zhou G, Guo L, Lu F, Zhou G. Comparison of clinical efficacy of metoprolol combined with irbesartan and hydrochlorothiazide and non-invasive ventilator in the emergency treatment of patients with severe heart failure. Exp Ther Med. 2018 Dec;16(6):5059-5066. doi: 10.3892/etm.2018.6828. Epub 2018 Oct 4. PubMed PMID: 30542460; PubMed Central PMCID: PMC6257578. 2: Ashour S, Bayram R. Selective and validated kinetic spectrophotometric method for the determination of irbesartan in pure and pharmaceutical formulations. Ann Pharm Fr. 2018 Nov 21. pii: S0003-4509(18)30114-7. doi: 10.1016/j.pharma.2018.09.002. [Epub ahead of print] PubMed PMID: 30471775. 3: Hoffmann M, Chen X, Hirano M, Arimitsu K, Kimura H, Higuchi T, Decker M. (18) F-Labeled Derivatives of Irbesartan for Angiotensin II Receptor PET Imaging. ChemMedChem. 2018 Dec 6;13(23):2546-2557. doi: 10.1002/cmdc.201800638. Epub 2018 Nov 15. PubMed PMID: 30430750. 4: Li T, Yao W. Therapeutic effect of irbesartan combined with atorvastatin calcium in the treatment of rats with coronary heart disease. Exp Ther Med. 2018 Nov;16(5):4119-4123. doi: 10.3892/etm.2018.6669. Epub 2018 Aug 30. PubMed PMID: 30402154; PubMed Central PMCID: PMC6200972. 5: Boccellino M, Di Domenico M, Donniacuo M, Bitti G, Gritti G, Ambrosio P, Quagliuolo L, Rinaldi B. AT1-receptor blockade: Protective effects of irbesartan in cardiomyocytes under hypoxic stress. PLoS One. 2018 Oct 24;13(10):e0202297. doi: 10.1371/journal.pone.0202297. eCollection 2018. PubMed PMID: 30356256; PubMed Central PMCID: PMC6200178. 6: Mohamed EA, Ahmed HI, Zaky HS. Protective effect of irbesartan against doxorubicin-induced nephrotoxicity in rats: implication of AMPK, PI3K/Akt, and mTOR signaling pathways. Can J Physiol Pharmacol. 2018 Dec;96(12):1209-1217. doi: 10.1139/cjpp-2018-0259. Epub 2018 Oct 23. PubMed PMID: 30351976. 7: Hu S, Cheng J, Weinstock J, Fan X, Venners SA, Hsu YH, Suwen Wu, Pan F, Zha X, Sun J, Jiang S, Xu X. A gender-specific association of the polymorphism Ile197Met in the kininogen 1 gene with plasma irbesartan concentrations in Chinese patients with essential hypertension. J Hum Hypertens. 2018 Nov;32(11):781-788. doi: 10.1038/s41371-018-0119-1. Epub 2018 Oct 3. PubMed PMID: 30283089. 8: Bikos A, Loutradis C, Aggeloudi E, Karpetas A, Raptis V, Kalaitzidis R, Panagoutsos S, Pasadakis P, Balaskas I, Liakopoulos V, Papagianni A, Sarafidis PA. The effects of nebivolol and irbesartan on postdialysis and ambulatory blood pressure in patients with intradialytic hypertension: a randomized cross-over study. J Hypertens. 2018 Jul 30. doi: 10.1097/HJH.0000000000001891. [Epub ahead of print] PubMed PMID: 30063644. 9: Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, Bowman L, Brunskill N, Cockwell P, Hill M, Kalra PA, McMurray JJV, Taal M, Wheeler DC, Landray MJ, Baigent C. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. Circulation. 2018 Oct 9;138(15):1505-1514. doi: 10.1161/CIRCULATIONAHA.118.034818. PubMed PMID: 30002098. 10: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK501626/ PubMed PMID: 30000687. 11: Mutha VVSRNAK, Guduru S, Kaliyaperumal M, Rumalla CS, Maddi SR, Korupolu RB, Gajbhiye SB. Degradation study of irbesartan: Isolation and structural elucidation of novel degradants. J Pharm Biomed Anal. 2018 Aug 5;157:180-188. doi: 10.1016/j.jpba.2018.05.009. Epub 2018 May 12. PubMed PMID: 29803909. 12: Kabel AM, Alzahrani AA, Bawazir NM, Khawtani RO, Arab HH. Targeting the proinflammatory cytokines, oxidative stress, apoptosis and TGF-β1/STAT-3 signaling by irbesartan to ameliorate doxorubicin-induced hepatotoxicity. J Infect Chemother. 2018 Aug;24(8):623-631. doi: 10.1016/j.jiac.2018.03.010. Epub 2018 May 9. PubMed PMID: 29753615. 13: Chen Y, Liu P, Chen X, Li Y, Zhang F, Wang Y. Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy. Am J Med Sci. 2018 May;355(5):418-424. doi: 10.1016/j.amjms.2018.01.017. Epub 2018 Feb 2. PubMed PMID: 29753370. 14: Pei Q, Liu JY, Yin JY, Yang GP, Liu SK, Zheng Y, Xie P, Guo CX, Luo M, Zhou HH, Li X, Liu ZQ. Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population. Eur J Clin Pharmacol. 2018 Aug;74(8):1021-1028. doi: 10.1007/s00228-018-2477-6. Epub 2018 May 11. PubMed PMID: 29748863. 15: Cheng YZ, Yang SL, Wang JY, Ye M, Zhuo XY, Wang LT, Chen H, Zhang H, Yang L. Irbesartan attenuates advanced glycation end products-mediated damage in diabetes-associated osteoporosis through the AGEs/RAGE pathway. Life Sci. 2018 Jul 15;205:184-192. doi: 10.1016/j.lfs.2018.04.042. Epub 2018 Apr 24. PubMed PMID: 29702126. 16: Abdel-Wahab AF, Bamagous GA, Al-Harizy RM, ElSawy NA, Shahzad N, Ibrahim IA, Ghamdi SSA. Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy. Biomed Pharmacother. 2018 Jul;103:59-66. doi: 10.1016/j.biopha.2018.03.176. Epub 2018 Apr 7. PubMed PMID: 29635129. 17: Shahin NN, Abdelkader NF, Safar MM. A Novel Role of Irbesartan in Gastroprotection against Indomethacin-Induced Gastric Injury in Rats: Targeting DDAH/ADMA and EGFR/ERK Signaling. Sci Rep. 2018 Mar 9;8(1):4280. doi: 10.1038/s41598-018-22727-6. PubMed PMID: 29523851; PubMed Central PMCID: PMC5844881. 18: Li L, Li J, Yi J, Liu H, Lei H. Dose-Effect of Irbesartan on Cyclooxygenase-2 and Matrix Metalloproteinase-9 Expression in Rabbit Atherosclerosis. J Cardiovasc Pharmacol. 2018 Feb;71(2):82-94. doi: 10.1097/FJC.0000000000000544. PubMed PMID: 29420356. 19: Wang X, Li G. Irbesartan prevents sodium channel remodeling in a canine model of atrial fibrillation. J Renin Angiotensin Aldosterone Syst. 2018 Jan-Mar;19(1):1470320318755269. doi: 10.1177/1470320318755269. PubMed PMID: 29378480; PubMed Central PMCID: PMC5843850. 20: Dalsania S, Sharma J, Munjal B, Bansal AK. Impact of Drug-Polymer Miscibility on Enthalpy Relaxation of Irbesartan Amorphous Solid Dispersions. Pharm Res. 2018 Jan 9;35(2):29. doi: 10.1007/s11095-017-2296-y. PubMed PMID: 29368174.